Targets › ESRRG
1 program from 1 company in 1 trial: 1 Phase 2; Oncology.
Orphan receptor that acts as a transcription activator in the absence of bound ligand. Binds specifically to an estrogen response element and activates reporter genes controlled by estrogen response elements (By similarity). (UniProt, P62508)
Open in Phaseline: the race on ESRRG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Northwestern University | Afimoxifene Estrogen receptor modulator; Estrogen-related receptor gamma antagonist | ESR2, ESR1, ESRRG | Phase 2 | Cancer Survivor | – |
Cancer Survivor (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.